HaRo Pharmaceutical, another new Port company, is conducting research and development focused on the treatment of high-risk neuroblastoma, funded by the National Cancer Institute (NCI). HaRo was the only small molecule therapeutic company — out of 75 startups nationwide — admitted to the Innovation Corps Team Training Pilot Program (ICORPS), an NCI/ National Institutes of Health -sponsored intensive commercial development course. Hyalo Technologies is a biotech and pharmaceutical company developing an innovative nanotechnology drug delivery system that promises to drastically reduce systemic side effects and increase patient compliance. Potential applications include cancer, pain management, wound healing and dermatology.